|
|
|
|
| | | | USD | EUR | GBP | JPY | 83.34 | 89.43 | 104.26 | 0.53 |
| | | | AED | AUD | CHF | CAD | 17.54 | 49.53 | 64.49 | 50.06 |
| | | | HKD | SAR | SGD | ZAR | 8.28 | 17.22 | 47.46 | 4.57 |
|
|
|
|
|
|
|
|
|
|
|
Industry :
|
Pharmaceuticals & Drugs
|
|
|
|
|
|
|
|
|
|
52-Week-High (Rs.)
|
1098.00
|
|
|
|
|
|
|
* BSE PRICES
|
|
|
|
|
|
(Rs. in Million) | Particulars | Dec 2023 | Sep 2023 | Jun 2023 | Mar 2023 | Audited / UnAudited | UnAudited | Audited | UnAudited | Audited | Net Sales | 13,650.96 | 22,334.16 | 21,443.84 | 19,390.48 | Total Expenditure | 15,493.64 | 17,899.26 | 16,593.88 | 17,213.77 | PBIDT (Excl OI) | -1,842.68 | 4,434.90 | 4,849.96 | 2,176.71 | Other Income | 2,588.15 | 735.78 | 493.61 | 2,329.65 | Operating Profit | 745.47 | 5,170.68 | 5,343.57 | 4,506.36 | Interest | 736.04 | 581.87 | 619.34 | 588.60 | Exceptional Items | -252.83 | -196.69 | -316.29 | -6,583.72 | PBDT | -243.40 | 4,392.12 | 4,407.94 | -2,665.96 | Depreciation | 511.62 | 498.46 | 487.52 | 467.29 | Profit Before Tax | -755.02 | 3,893.66 | 3,920.42 | -3,133.25 | Tax | -550.93 | 870.12 | 1,203.86 | -1,758.56 | Provisions and contingencies | 0 | 0 | 0 | 0 | Profit After Tax | -204.09 | 3,023.54 | 2,716.56 | -1,374.69 | Extraordinary Items | 0 | 0 | 0 | 0 | Prior Period Expenses | 0 | 0 | 0 | 0 | Other Adjustments | 0.00 | 0.00 | 0.00 | 0.00 | Net Profit | -204.09 | 3,023.54 | 2,716.56 | -1,374.69 | Equity Capital | 282.17 | 282.17 | 282.17 | 282.17 | Face Value (IN RS) | 1 | 1 | 1 | 1 | Reserves | | | | | Calculated EPS | -0.72 | 10.72 | 9.63 | -4.87 | Calculated EPS (Annualised) | -2.89 | 42.86 | 38.51 | -19.49 | No of Public Share Holdings | 150,550,469.00 | 150,550,469.00 | 150,550,469.00 | 150,550,469.00 | % of Public Share Holdings | 53.35 | 53.35 | 53.35 | 53.35 | | | | | | PBIDTM% (Excl OI) | -13.50 | 19.86 | 22.62 | 11.23 | PBIDTM% | 5.46 | 23.15 | 24.92 | 23.24 | PBDTM% | -1.78 | 19.67 | 20.56 | -13.75 | PBTM% | -5.53 | 17.43 | 18.28 | -16.16 | PATM% | -1.50 | 13.54 | 12.67 | -7.09 | | Notes | Notes | Notes | Notes |
|
|
|
|
|
|